
Bracco Diagnostics Inc. is a subsidiary of Bracco Imaging which is part of the overall Bracco Group. The Company specializes in the clinical development, marketing and sales of diagnostic contrast imaging agents. Bracco Diagnostics Inc. primarily markets its products to hospitals throughout the United States. Bracco Diagnostics Inc. is committed to the discovery, development, manufacturing and marketing of imaging agents and solutions aimed at providing a better use and management in terms of diagnostic efficacy, patient safety and cost effectiveness.
This position primarily encompasses market development and promotional activities for Bracco’s cardiovascular PET agent, CardioGen-82. The Molecular Imaging Account Manager, Cardiology position involves direct interface with a variety of customers. These customers include nuclear cardiologists, nuclear medicine physicians and radiologists, nuclear medicine technologists, nursing personnel, business administrators and financial officers, and nuclear pharmacists. Business interface with nuclear (SPECT & PET) camera equipment vendors, radio pharmacies, and providers of Imaging services both Mobile and free-standing imaging centers is also required.
The territory covered for this role will be the Mid-Atlantic and include the following states: Ohio, West Virginia, and Virginia. Candidates residing within the territory, specifically in Cleveland, Columbus, Charleston, WV, Richmond, and Roanoke are HIGHLY preferred.
To perform this job successfully, an individual must be able to perform each essential duty satisfactorily. The requirements listed below are representative of the knowledge, skill, and/or ability required. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.
Adhere to the Bracco’s core values, including:
Bracco Diagnostics Inc. is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, sexual orientation, gender identity, or any other protected status.

Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,700 employees and annual total consolidated revenues of around 1,7 billion euros, 89% of which from international sales. In the R&D area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors. The Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Bracco offers an extensive and innovative portfolio of products and solutions for all diagnostic modalities completed by several medical devices and advanced administration systems for contrast imaging products in the fields of cardiology and radiology, developed by it’s American company ACIST. Since its foundation, Bracco has been a socially responsible company in each area of activity - in business as in every other context. Its subsidiary Bracco Imaging is one of the world’s leading companies in the diagnostic imaging field :X-Ray Imaging (including Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound, and Nuclear Medicine. The Company operates in over 110 markets: in North America through Bracco Diagnostics Inc. USA , and with an affiliate in Montreal (Canada); in Europe, with offices in all major countries; in Japan (BRACCO-EISAI). The Company also operates in South America, South Korea and China through its 70% controlled Joint Venture, Bracco Sine Pharmaceutical Corp. Ltd.